Skip to main content

Table 2 Associations between clinicopathological variables and p53 functionality

From: Integral analysis of p53 and its value as prognostic factor in sporadic colon cancer

  p53 non functional N (%) p53 functional N (%) p value
TP53 mutational status    
wt 7 (33) 14 (78) 0.01
mut 14 (67) 4 (22)  
P53 IHC    
0 3 (11) 7 (24) <0.001#
0 - ≤25% 1 (3) 22 (76)  
>25% 24 (86) 0 (0)  
Chr. 17 p status    
AB 5 (18) 22 (76) <0.001*
LOH 2 (7) 4 (14)  
Copy neutral LOH 9 (32) 0 (0)
Amplified LOH 5 (18) 1 (3)
Allelic Imbalance 1(4) 0 (0)
Two clones 6 (21) 2 (7)
Age category    
50 – 59 4 (14) 6 (22) NS
60 – 69 10 (36) 9 (32)  
70 – 79 10 (36) 9 (32)  
80 – 89 4 (14) 4 (14)  
DNA index    
0.95 – 1.05 6 (22) 21 (78) <0.001¶
1.06 – 1.4 4 (15) 3 (11)  
1.41 – 1.95 17 (63) 3 (11)  
MMR status    
MSI 4 (14) 14 (50) 0.009
MSS 24 (86) 14 (50)  
Gender    
Male 12 (43) 18 (62) NS
Female 16 (57) 11 (38)  
Tumor Location    
Right 10 (36) 19 (66) 0.035
Left 18 (64) 10 (34)  
Stage    
I and II 14 (50) 22 (76) 0.06
III 14 (50) 7 (24)  
Median Follow up in months 66.75 89.77 0.4
  1. 2 test allelic status AB vs. LOH p=0.58; AB vs. CNLOH p<0.001; AB vs. ALOH p=0.005; AB vs. two clones p=0.006
  2. LOH vs. CNLOH p=0.01; LOH vs. ALOH p=0.24; LOH vs. two clones p=0.28.
  3. ALOH vs. CNLOH p=0.43; Amp LOH vs. two clones p=1.
  4. CNLOH vs. two clones p=0.48.
  5. # Χ2 test p53 IHC 0 vs. 0-25% p=0.07; 0 vs. >25% p<0.001; 0-25% vs. >25% p=0.001.
  6. ¶ Χ2 test DNA index 0.95 – 1.05 vs. 1.06 – 1.4 p=0.16; 0.95 – 1.05 vs. 1.41- 1.95 p<0.001; 1.06 – 1.40 vs. 1.41 – 1.95 p=0.29.